CR1525MK - Advance Solid Tumor – Pembrolizumab
Study drug: Pembrolizumab 200 mg intravenously every 3 weeks (Q3W)
Main Inclusion criteria:
- Any advanced solid tumor which is Microsatellite Instability (MSI)-High (MSI-H)
- There is no limit to the number of prior treatment regimens
- Can supply tumor tissue for study analyses
Main Exclusion criteria:
- Active autoimmune disease that has required systemic treatment in the past 2 years
- Previously participated in any other pembrolizumab (MK-3475) study, or received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1), anti-PD-L2
[Details]
CA209-848 Solid Tumors of High Tumor Mutational Burden (TMB-H) Nivolumab +/- Ipilimumab
Main Inclusion Criteria:
- Solid malignant tumor with TMB-H
- Available tumor tissue and blood for TMB testing
- Measurable disease
Main Exclusion Criteria:
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, or anti-CTLA-4 antibody [Details]
CAPTUR (Canadian Profiling and Targeted Agent Utilization Trial)
Study Drug: targeted therapies
Main Inclusion Criteria: (screening step - non-drug specific)
- Tumour genomic or protein expression testing
- Patients must have measurable disease
- ECOG performance status 0-2.
Main Exclusion criteria:
- Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician [Details]